A B S T R A C T Prostaglandin (PG)D2
A B S T R A C T Prostaglandin (PG) D2 is synthesized in platelets at concentrations which could inhibit aggregation via activation of adenylate cyclase. To more directly define platelet-PG interactions, a binding assay has been developed for platelet PG receptors with [3H]PGD2 as ligand.
[3H]PGD2 binding to intact platelets was saturable and rapid with the ligand bound by 3 ,uM) > PGI2 (IC50 = 2 ,uM) > PGE, (IC50 = 6 AM) > PGF2o, (IC50 = 8 ,uM). Scatchard analysis of binding data from six normal subjects showed a single class of binding sites with a dissociation constant (Kd) of 53 nM and 210 binding sites per platelet. This PGD2 receptor assay was then used to study platelets from five patients with myeloproliferative disorders (polycythemia vera, essential thrombocythemia, and chronic myelogenous leukemia), as over 90% of these patients have platelets resistant to the effects of PGD2 on aggregation and adenylate cyclase activity (1978. Blood. 52: 618-626.). In the presence of 50 nM [3H]PGD2, the patients' platelets bound 7.1±2.9 fmol ligand108 platelets compared with 15 .1±1 fmol/108 platelets in normals, a decrease of 53% (P < 0.01). Scatchard analysis showed that the Kd of [3H]PGD2 binding (33 nM) was comparable to normal platelets, which indicates that the decreased PGD2 binding in these platelets represented fewer receptors rather than altered affinity ofthe ligand for the binding site. The 53% decrease in [3H]PGD2 binding correlated with a 48% decrease in PGD2-activated platelet adenylate cyclase. The characterization
INTRODUCTION
There is increasing evidence that prostaglandins and their derivatives may regulate platelet aggregation (1). Whereas certain prostaglandin (PG)l intermediates such as PGG2 and PGH2, as well as thromboxanes, may induce platelet aggregation, other stable PG such as PGI2, PGE, and PGD2 are potent inhibitors of platelet aggregation via activation of adenylate cyclase (2) (3) (4) (5) (6) (7) (8) (9) . PGI2 is synthesized by endothelial cells and may play an important role in mediating platelet-endothelial cell interactions (2) . However, of these PG only PGD2 is produced by platelets at sufficient concentrations to potentially inhibit platelet aggregation (9) . As (14) . Platelets from these patients require higher than normal concentrations of PGD2 to inhibit collagen-induced serotonin release, and stimulation of platelet adenylate cyclase by PGD2 is blunted. These studies provide the initial characterization ofthe platelet PGD2 receptor and demonstrate its use in studying the PGD2 receptor in platelets from patients with myeloproliferative disorders.
METHODS
Binding assay. Platelet-rich plasma was obtained from 200 ml of venous blood anticoagulated with 13.5% acid citrate dextrose (National Institutes of Health Formula A) by centrifugation at 160 g for 10 min. The platelet-rich plasma was adjusted to pH 6.5 with additional acid citrate dextrose, and a platelet pellet was prepared by centrifugation at 1,500 g for 10 min. The pellet was suspended in 10 ml of buffer containing 8 mM Na2HPO4, 2 mM NaH2PO4, 10 mM EDTA, 5 mM KC1, and 135 mM NaCl, pH 7.2, and recentrifuged at 1,500g for 10 min. The supernate was discarded, and the platelet pellet was resuspended in 3.5 ml of assay buffer (138 mM NaCl, 5 (Fig. 3) (14) and found that these patients required 10-fold higher than normal concentrations of PGD2 to inhibit collageninduced platelet serotonin release. Whereas (6) (7) (8) (9) . Characterization of the PGD2 platelet receptor, as well as the identification of certain platelets that have decreased number of these receptors, may lead to a better understanding of platelet-PG interactions.
